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a  b  s  t  r  a  c  t
Aﬂatoxin  B1 is  a carcinogen  produced  by  Aspergillus  ﬂavus  and  a few  related  fungi  that are  often  present
in  many  food  substances.  It interacts  synergistically  with  Hepatitis  B or  C virus  (HBV,  HBC)  infection,
thereby  increasing  the  risk  of  hepatocellular  carcinoma  (HCC).  The  G to  T transversion  at  the  third  position
of  codon  249  (AGG)  of  the  TP53  gene,  substituting  arginine  to  serine,  is  the  most  common  aﬂatoxin-
induced  mutation  linked  to HCC.  This  study  examined  mutations  in TP53  by  PCR-RFLP  analysis  and  by
measurement  of  an aﬂatoxin-albumin  adduct  as a biomarker  for  human  exposure  of aﬂatoxin  B1  by
indirect-competitive  ELISA,  in samples  collected  from  healthy  controls  as  well  as patients  with  hepatitis
in  Hyderabad,  Andhra  Pradesh,  India.  A total  of 238  blood  samples  were  analyzed  the  presence  of  the  G to
T  mutation.  Eighteen  of these  samples  were  from HBV-positive  subjects,  112  of these  were from  subjects
who  had HBV-induced  liver  cirrhosis,  and  108 samples  were  taken  from  subjects  without  HBV  infection
or  liver  cirrhosis  (control  group).  The  G  to T mutation  was  detected  in  10 samples,  8 of which  were
from  subjects  positive  to both HBV  and  aﬂatoxin-albumin  adduct  in blood  (p = 0.07);  whilst  two  were
from  individuals  who  were  HBV-negative,  but positive  for the  aﬂatoxin-albumin  adduct  (p =  0.14).  The
aﬂatoxin-albumin  adduct  was  detected  in 37  of  238  samples,  29  samples  were  from  HBV-positive  subjects
and  eight  were  from  individuals  who  were  positive  for both  HBV  and  the  TP53  mutation  (p =  0.07).  The
concentration  of  aﬂatoxin-albumin  adduct  ranged  from  2.5  to 667  pg/mg  albumin.  Despite  low  incidence
of  the  G  to  T mutation,  its detection  in subjects  positive  to aﬂatoxin-adducts  is  indicative  of  a strong
association  between  the  mutation  and aﬂatoxin  exposure  in India.
© 2014  Elsevier  B.V.  All rights  reserved.
1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most common can-
cer in the world, accounting for about 5% of all human cancers,
and the second cause of death from cancer worldwide [1]. It is the
ﬁfth most common cancer in men  and the eighth most common
cancer in women [2]. The incidence of HCC in India is reported to
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be between 0.2% and 1.9% [3]. Infection with hepatitis B or C virus
is considered to be the major cause for HCC. The hepatitis B virus
(HBV) is highly prevalent in the developing world, with an esti-
mated two billion people infected. In India, HBV prevalence among
the general population ranges from 2% to 8%, placing India in the
intermediate HBV-endemic zone, where the number of HBV carri-
ers is estimated to be 50 million, forming the second largest global
pool of chronic HBV infections [4]. Previous studies have implicated
a multifaceted etiology for human HCC [5]. In addition to chronic
infection with hepatitis B or C viruses and lifestyle habits (such as
alcohol abuse), dietary exposure to aﬂatoxin B1 (AFB1) is a major
risk factor for development of human HCC [5,6], especially where
exposure to HBV is endemic.
http://dx.doi.org/10.1016/j.mrgentox.2013.12.011
1383-5718/© 2014 Elsevier B.V. All rights reserved.
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Mycotoxins are toxins produced by certain fungi, and aﬂatox-
ins are an important group of mycotoxins produced by the fungi
Aspergillus ﬂavus and Aspergillus parasiticus,  which contaminate sta-
ple foods including groundnuts [2]. The etiologic involvement of
AFB1 in human HCC can be inferred from the high incidence of
this disease in certain geographical regions, particularly, South and
Southeast Asia and sub-Saharan Africa, where the warm and humid
climate promotes mold growth and contamination of food sup-
plies by this naturally occurring mycotoxin [5,6]. Several studies
have shown that aﬂatoxin contamination is frequent in food crops
grown in Asia and sub-Saharan Africa [7]. AFB1 is metabolized by
P450 enzymes in the liver and generates an epoxide that is highly
reactive with DNA, forming adducts at the N7 position of guanine. If
not repaired, these lesions may  lead to permanent DNA mutations,
preferentially G to T transversions [2]. The epoxides are detoxiﬁed
to a limited extent by glutathione S-transferase (GST)-mediated
conjugation with reduced glutathione (GSH) to form AFB1 exo- and
endo-epoxide-GSH conjugates [8]. The most common aﬂatoxin-
induced mutational hot spot found in HCCs in more than 50% of
cases reported from different geographical regions, such as China
and southern Africa, is a G to T transversion at the third position
of codon 249 (AGG) of the TP53 gene, which results in the sub-
stitution of arginine by serine [1,9]. However, very little is known
about the prevalence of aﬂatoxin exposure and its impact on liver
disorders in HBV-positive patients in India. Earlier reports on liver-
biopsy samples suggest that the frequency of TP53 mutation is low
in India [10]. Another study measured AFB1 exposure in 4.5% of
HBV-positive samples in India [11].
This study was undertaken to determine the association
between infection with HBV, exposure to aﬂatoxin, and mutation
in codon 249 of TP53, in blood samples of patients with different
stages of liver disease. This work is based on a model for end-stage
liver disease (MELD) in 130 subjects positive for HBV and/or suf-
fering from liver cirrhosis, and 108 samples from a healthy control
group (hepatitis B- or C-negative, no liver disorder).
2. Materials and methods
2.1. Sample collection
Samples were collected from two  hospitals in Hyderabad during the years 2009
and 2010. Patients with clinically conﬁrmed liver disorders (decompensated liver
disease) were selected for this study. A total of 238 blood samples were collected, of
which 130 blood samples were from patients with liver diseases, and 108 samples
were from the control group comprising individuals living in the same household
as the diseased subject, but without any history of liver disease. Demographic data
(age,  sex, address, clinical signs), family history of liver disease, lifestyle habits such
as tobacco use and alcohol consumption, dietary proﬁle, clinical and laboratory pro-
ﬁles including results from liver-function tests, were recorded. Clinical and dietary
proﬁles of each patient were documented by use of a standard questionnaire. The
clinical proﬁle of a subject was  used to identify the stage of liver disease with the
‘Model for end-stage liver disease’ (MELD) and ‘Child Turcotte Pugh’ (CTP) scoring
systems [12]. All the objectives of the study were clearly explained to the participat-
ing individuals, and written consent was obtained before collecting blood samples.
The study was approved by the Ethics Committee of the Nizam’s Institute of Medical
Sciences, Hyderabad.
2.2. Scoring the severity of liver disease based on clinical proﬁle
MELD and CTP scoring-systems were used to determine the severity of liver
disease. Based on liver-function tests for serum creatinine, total bilirubin, and
international normalized ratio (INR), a MELD score was  calculated to quantify the
end-stage liver disease for each patient with the following scoring equation pro-
posed by The Mayo Clinic group [13]:
3.8 Lg[totalbilirubin(mg/dl)] + 11.12 Lg(INR) + 9.6 Lg[creatinine(mg/dl)]
+  6.4(Aetiology : 0ifcholestaticoralcoholic, 1ifotherwise).
The CTP scoring-system involves allotting points for albumin level, ascites, total
bilirubin, prothrombin time and hepatic encephalopathy, and scores can vary from
5  to 15 (Table 1). Based on total score, patients are designated as Child’s class A (CTP
5–6), class B (CTP 7–10) and class C (CTP 11–15).
Table 1
Severity of liver disease according to the Child Turcotte Pugh (CTP) scoring system.
Parameter* Points**
1 2 3
Hepatic encephalopathy None Grade 1–2 Grade 3–4
Ascites (peritoneal cavity ﬂuid)
measured by abdominal
ultrasound
Absent Slight Moderate
Serum albumin (mg/dl) >3.5 3.5–2.8 <2.8
Total bilirubin (mg/dl) <2 2–3 >3
International normalized ratio
(INR)
<1.7 1.7–2.3 >2.3
* Source = liver-function test records of subjects.
** Points assigned; CTP scores range between 5 and 15; CTP 5–6 = Child’s class A;
CTP  7–10 = Child’s class B; CTP 11–15 = Child’s class C [see Ref. [12]].
2.3. Detection of TP53 mutation by PCR ampliﬁcation and restriction-enzyme
digestion
DNA was  extracted from blood samples that were taken from the subjects and
collected in EDTA vials. Samples were kept in an ice-box and transferred to the
Mycotoxicology and Virology Lab at ICRISAT, Hyderabad, where they were stored
at −20 ◦C until processing time. DNA was extracted from 200 l of blood by use
of a commercial DNA-extraction kit (Nucleospin Blood, Cat # 740951, Macherey
Nagel, Germany) according to the manufacturer’s protocol. DNA was used for the
ampliﬁcation of a 254-bp portion of exon 7 surrounding codon 249 by means of the
polymerase chain-reaction (PCR) with primer pair p53Fser (5′ CTT GCC ACA GGT
CTC CCC AA 3′) and p53Rser (5′ AGG GGT CAG RGG CAA GCA  GA 3′), similar to the
primers used in earlier work in China [14]. PCR was  performed in a thermal cycler
(Applied Biosystems) with an initial denaturation step of 2 min at 94 ◦C followed by
40  cycles of denaturation at 94 ◦C for 30 s, annealing at 60 ◦C for 30 s, and extension
at  72 ◦C for 30 s. The ampliﬁed product (6 l) was digested with restriction enzyme
Hae III (New England Biolabs, UK) at 37 ◦C for 4 h. PCR products and Hae III-digested
products were analyzed by means of electrophoresis in a 2% TAE-agarose gel. The
gels  were stained with ethidium bromide and visualized on a UV-transilluminator.
2.4. Measurement of aﬂatoxin-albumin adducts
The AFB1-lysine (AFB1-lys) adduct found in human serum-albumin (HSA) was
used as a biomarker to assess exposure to aﬂatoxin of the subjects [11]. Five ml
of  blood sample were collected in plain vacutainers from 238 individuals. Serum
was  separated from each sample and processed to measure the amount of AFB1-lys
adduct by an indirect competitive enzyme-linked immunosorbent assay (IC-ELISA)
essentially as described by Anitha et al. [11]. This procedure involves extraction of
the albumin fraction from 500 l of serum, and measurement of its concentration
according to Bradford [15]. Two  mg of albumin was digested with proteinase K,  and
the digested product was analyzed in an IC-ELISA with an antibody produced against
AFB1-BSA conjugate [11]. Alkaline phosphatase-conjugated anti-rabbit antibodies
(AR-ALP) were used as a secondary antibody, and p-nitrophenyl phosphate (pNPP)
was applied as a substrate. The colorimetric reaction was followed on an ELISA plate-
reader with a 405-nm ﬁlter.
2.5. Statistical analysis
Samples were collected from 238 individuals with clinical proﬁles, food
(diet) consumption-related questionnaires and demographic data. These data were
entered in a database (SAS 9.2V) and used for statistical analysis with SAS 9.2V.
Pearson’s chi-square and Fisher’s exact tests were applied to assess the statistical sig-
niﬁcance of the frequency of independent variables and codon-249Ser mutations, by
means of the software SAS 9.2V. This helped to estimate the risk of mutation among
the study groups considering age, sex, HBV surface-antigen status, and aﬂatoxin-
exposure status as potential confounders.
3. Results
A total of 238 blood samples were analyzed for the presence of
TP53 gene mutations. The age of the subjects (64% men) ranged from
36 to 61 years, 130 individuals were HBV-positive and 108 nega-
tive. Among the HBV-positive samples, 112 were from subjects with
liver cirrhosis. The use of PCR primers p53Fser and p53Rser resulted
in ampliﬁcation of a 254-bp product in all 238 samples (Fig. 1). The
presence of a mutation in codon 249 was  assessed by RFLP of the
PCR product, by use of the Hae III enzyme that cleaves the GG↓CC
sequence at codon position 249–250, generating products of 92 bp,
Author's personal copy
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Table  2
TP53 mutation and AFB1-lys adducts in liver-cirrhosis and HBV serum-positive patients grouped by Child Turcotte Pugh (CTP) and Model for End-Stage Liver Disease (MELD)
scores.
CTP category Number of
samples
MELD Score Clinical condition Hepatitis B
virus
Number of samples with
mutation at position 249 of
the TP53 gene
Number of samples
positive for
AFB1-lysine
Mean adduct
level (pg/mg
albumin)
Not applicable
(control
group)
108 Not applicable (control group) None Negative 2 8 19.25
Child’s class A 18 Initial stage of liver disorder None Positive 0 18 18.1
Child’s class B 87 Decompensated liver disease Cirrhosis of liver Positive 5 8 71.25
Child’s class C 2 Decompensated liver disease Cirrhosis of liver Negative 2 2 77.5
Child’s class C 23 Decompensated liver disease Cirrhosis of liver Positive 1 1 575
Fig. 1. RFLP analysis with the Hae III enzyme to detect the TP53 mutation. Lanes
2  and 6, undigested (U) PCR products; lanes 3–5 and 7–9, PCR products digested
with Hae III;  lanes 1 and 10, 100-bp DNA-size standards (M). The lengths of the PCR
products are indicated with arrows. PCR products in lanes 3–5 are positive (+) for the
G→T  mutation at the 3rd base of the codon 249 in the TP53 gene; the PCR products
in  lanes 7–9 do not have the G→T mutation.
66 bp and several smaller fragments from the 254-bp PCR product.
In samples with a G→T mutation at codon 249, Hae III digestion
yields a 158-bp fragment due to loss of a restriction site (Fig. 1).
The G→T mutation at codon 249 of the TP53 gene was detected
in 10 samples (4.2%), eight of which were from subjects infected
with HBV and suffering from liver cirrhosis, and who also had
aﬂatoxin-albumin adduct (p = 0.07); the other two were from con-
trol subjects (HBV-negative, no liver disease) who  were positive for
the AFB1-1ys adduct (p = 0.14). In 37 of 238 samples analyzed, the
AFB1-lys adduct was found in the IC-ELISA. Among these, 29 sam-
ples were from subjects who had cirrhosis of the liver and were
positive for HBV, and eight samples were from individuals who
were positive for both HBV and mutation in TP53 (p = 0.07).
Of ten samples positive for mutation at codon 249 of TP53, two
were from the control group, ﬁve samples were in the Child-B and
three in the Child-C category, with the highest MELD scores with
decompensated liver disease (Table 2). These ten samples also had
a high amount of AFB1-lys adducts (>76 pg/mg albumin) (Table 3).
With a set p-value of 0.1, aﬂatoxin exposure (AFB1-lys) and TP53
Table 3
AFB1-lys in human serum albumin detected by IC-ELISA and TP53 mutation detected
by  PCR-RFLP.
Range of AFB1-lys adduct
concentration (pg/mg
albumin)
Number of
samples
Number of samples with
mutation at position 249 in
the TP53 gene
0a 201 –
2.5–25 17 –
26–50 7 –
51–75 4 2
>76 9 8
a No detectable AFB1-lys (optical density values equivalent to negative control).
mutation were dependent on each other, otherwise they were inde-
pendent (Table 4). This shows that TP53 mutation and AFB1-lys
adduct are dependent in HBV samples. Among the 37 individuals
who provided AFB1-lys-positive samples, eight were from the con-
trol group; 18 individuals were infected with HBV but did not show
any clinical condition and fell in the Child-A category with initial
stages of cirrhosis based on CTP and MELD scores; eight individ-
uals were positive for HBV and cirrhosis of the liver and fell in
the Child-B category with decompensated liver disease based on
CTP and MELD scores; two  had cirrhosis without HBV infection and
fell in the Child-C category with decompensated liver disease; and
one was infected with HBV, suffered from cirrhosis and fell in the
Child-C category with decompensated liver disease (Table 2).
There was  no signiﬁcant difference in the 249Ser mutation level
between females with HBV (p = 0.12) and males with HBV (p = 0.38).
This shows that sex has no inﬂuence on the presence of aﬂatoxin
and TP53 mutation. Similarly, daily consumption of rice and the
presence of AFB1-lys with TP53 mutation in HBV-positive individ-
uals had no signiﬁcant inﬂuence (p = 0.19). With a set p-value of
0.1, the inﬂuence of aﬂatoxin exposure and TP53 mutation in non-
alcoholic individuals with liver disease and HBV-positive status
were dependent on each other, otherwise they were indepen-
dent (p = 0.05) (Table 4). The concentration of the AFB1-lys adduct
ranged from 2.5 to 677 pg/mg albumin with a mean adduct level of
52.1 pg/mg. Interestingly, the individuals positive for both HBV and
TP53 mutation had an AFB1-lys level >75 pg/mg albumin (Table 3).
This level was  higher than that of individuals positive for HBV and
without mutation (<75 pg/mg albumin). The MELD score showed
that the presence of HBV together with AFB1-lys produced a higher
mutation percentage, and all patients had decompensated liver dis-
ease (Table 2).
4. Discussion
Carcinogenesis is a multistep process, and the interaction of
host-cell factors along with viral and chemical carcinogens appears
to play a key role in the development of hepatocellular carcinoma
in humans [10]. When the liver is exposed to HBV, the hepatocytes
are injured and undergo structural changes [15]. Dietary exposure
to AFB1 leads to the formation of aﬂatoxin epoxide, which is highly
reactive and binds to albumin, which is a major plasma protein
produced in liver cells. It also binds to DNA, forming adducts at
the N7 position of guanine [16,17]. A lack of repair may  give rise
to mutations in the TP53 gene, which may  lead to the loss of its
tumour-suppressor function and uncontrolled proliferation of liver
cells, which may  result in HCC. The transformation of a normal
cell to a cancer cell is a complex process, accompanied by multiple
steps of genetic and epigenetic alterations [18]. Although a diverse
set of genes has been implicated in tumourigenesis, the transcrip-
tion factor p53 (encoded by the human gene TP53) stands out as
Author's personal copy
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Table  4
Demographic data of the study group categorized by HBV infection (serum Ag-positive), sex, alcohol consumption, and staple diet.
Parameter No of samples Mutation at 249
position in p53 gene
AFB1-lys
adduct positive
Positive for mutation
and AFB1-lys adduct
p-Value**
Serum hepatitis B
Positive 130 (54.6) 8 (6.1) 29 (22.0) 4 (3.0) 0.07
Negative 108 (45.4) 2 (1.8) 8 (7.4) 1 (0.9) 0.14
Sex
Male
Hepatitis B-positive 88 (67.6) 7 (7.9) 24 (27.2) 4 (4.5) 0.38
Hepatitis B-negative 65 (60.1) 2 (3) 7 (10.7) 1 (1.5) 0.21
Female
Hepatitis B-positive 42 (32.3) 1 (1.17) 5 (5.8) 1 (2.3) 0.12
Hepatitis B-negative 43 (39.8) 0 (0) 1 (1.17) 0 (0) *
Alcohol consumption
Alcoholic
Hepatitis B-positive 21 (16.1) 0 (0) 6 (28.5) 0 (0) *
Hepatitis B-negative 1 (0.92) 0 (0) 0 (0) 0 (0) *
Non-alcoholic
Hepatitis B-positive 109 (83.8) 8 (7.3) 23 (21.1) 4 (3.6) 0.05
Hepatitis B-negative 107 (99.0) 2 (1.9) 8 (7.5) 1 (0.9) 0.14
Staple diet
Rice
Hepatitis B-positive 117 (90.0) 2 (1.7) 16 (13.6) 2 (1.7) 0.19
Hepatitis B-negative 100 (92.5) 1 (1) 0 (0) 1 (1) *
Rice and wheat
Hepatitis B-positive 13 (10.0) 6 (46.1) 13 (100) 4 (30.7) *
Hepatitis B-negative 8 (7.4) 1 (12.5) 8 (100) 0 (0) *
Values in parentheses are percentages.
* Means row or column sum zero (no statistics is computed).
** Probability obtained by Pearson’s chi-square and Fisher’s exact tests.
a key tumour-suppressor gene [19]. The role of TP53 as a tumour-
suppressor gene includes the ability to induce cell cycle arrest, DNA
repair, senescence, and apoptosis [20]. The TP53 gene in human
tumours is often found to undergo missense mutation, where a
single nucleotide is substituted with another [21]. Consequently, a
full-length protein containing only a single amino-acid substitution
is produced, which results in loss of its suppressor activity. It is well
established that p53 inactivation and expression of mutant p53 can
confer cells with additive growth and survival advantages, such as
increased proliferation, evasion of apoptosis, and chemo-resistance
[18].
Globally, 600,000 people die every year due to infection with
Hepatitis B [22]. In the Middle-East and on the Indian sub-
continent, 2–5% of the general population is chronically infected
with Hepatitis B virus [22]. In India, few studies previously indi-
cated that AFB1 exposure is one of the important and possible
risks for liver cancers [23]. However no study has been conducted
in India to map  the associations among aﬂatoxin exposure, TP53
mutations and liver diseases in tandem. In our study, we made an
attempt to look into these complex relationships. Surprisingly, of
238 patients analyzed, 10 patients were positive for TP53 mutation,
and all of them were positive for AFB1-lys, an indication of aﬂatoxin
exposure. Frequencies of aﬂatoxin exposure, TP53 mutation and
HBV, with p-values in the Chi-square test and in Fisher’s exact test
were analyzed (Table 4). There were eight samples from individuals
with high aﬂatoxin exposure (protein adduct level >76 pg/mg albu-
min) and TP53 mutation and two samples from subjects with low
aﬂatoxin-protein levels (<76 pg/mg albumin) (Table 3). This shows
that the level of AFB1-lys may  raise the probability of obtaining
a TP53 mutation. Although the number of mutations is low, it is
still considerable when taking 138 cirrhosis samples into consid-
eration. In the study group, 216 individuals were non-alcoholic.
Among them, 23 HBV-positive individuals had the AFB1-lys adduct
in their blood and eight of them had a TP53 mutation (p = 0.05)
(Table 4). Among the 22 alcoholics, not one had a TP53 mutation.
These data indicate a link between the occurrence of a mutation at
codon 249 with the presence of aﬂatoxin-albumin adduct in blood,
which is an indication of exposure to dietary aﬂatoxins.
No signiﬁcant correlation was observed between consumption
of rice and the presence of aﬂatoxin-albumin adducts with TP53
mutation (Table 4). People in southern India consume diverse foods
apart from rice (corn, wheat, chillies and groundnuts) every day.
This may  have a cumulative effect on the presence of aﬂatoxin-
albumin adduct in the blood. It is difﬁcult to determine the exact
contributing dietary source of aﬂatoxin unless the foods themselves
are analyzed for aﬂatoxin.
The results of the present study show an association between
HBV and AFB1 in patients with liver disorders. An earlier study
conducted in India [10] on TP53 tumour-suppressor gene muta-
tions in 21 patients with HCC, revealed a low frequency (9.5%;
95% CI, 22.1–23.0) of TP53 gene mutation at codon 249, the most
common mutational hot spot in HCC. A low frequency of TP53
mutation involving codon 249 has also been reported in Germany,
Taiwan, and Thailand [24–26]. The levels of dietary exposure to
aﬂatoxin in Thailand and the presence of the mutated DNA in
plasma is consistent with the notion that exposure to this toxin,
together with chronic HBV infection remains a major etiologi-
cal factor for HCC in Thailand [2]. The aﬂatoxin level in India
was high in non-carriers of HBV, which is indicative of the inde-
pendent role played by AFB1 in hepatocarcinogenesis [3]. With
68.7% of the non-B non-C hepatitis patients having tissue local-
ization of AFB1, and the concomitant presence of AFB1 along
with HBV in 46.1% of cases studied, HBV is an additional risk fac-
tor to which populations from developing countries are exposed,
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and it plays an aggravating role in hepatocarcinogenesis. This
statement is supported by the current study in which 22% of HBV-
positive cases had aﬂatoxin-albumin adduct, of which 8% had a
TP53 mutation. Interestingly, 7.4% of individuals in the healthy
control group (HBV-negative, no liver disease) had the aﬂatoxin-
albumin adduct and 1.8% of these had a TP53 mutation, with a
high aﬂatoxin-albumin level, ranging between 300 and 600 pg/mg
albumin.
The MELD and CTP scores were used to identify the severity
of liver disease. MELD and CTP scores are complementary to each
other in evaluating the progressive clinical condition of liver cir-
rhosis [27]. They also provide the advantage of ranking patients
according to the severity of the underlying liver disease and risk of
mortality [12]. The total CTP score ranged between 5 and 15. Those
classiﬁed as CTP 5–6 fall under Child’s class A, CTP 7–10 fall under
Child’s class B and CTP 11–15 falls under Child’s class C (Table 1).
The survival of individuals decreases with a Child’s score of 7 or
greater, i.e., Child’s class B or C. The scoring is done based on hepatic
encephalopathy, presence of ascites, albumin, total bilirubin level,
prothrombin time and international normalized ratio (INR) for pro-
thrombin time.
The MELD score was  calculated by use of serum creatinine, total
bilirubin, INR and underlying etiology for end-stage liver disease.
Status-1 patients are those with the highest MELD score and where
the liver is considered severely decompensated. The presence of
aﬂatoxin-albumin, together with hepatitis B and cirrhosis of the
liver, increases the severity of liver disease that can be interpreted
from different stages and severity (Child A/B/C) based on CTP and
MELD score (Table 2).
The MELD and CTP scores were compared with the presence of
aﬂatoxin and TP53 mutation, along with Hepatitis B infection. The
results show that there is critical link between the aﬂatoxin pres-
ence together with Hepatitis B and cirrhosis of the liver to elicit and
increase the severity of liver disease (Table 2). Whenever HBV infec-
tion or exposure to aﬂatoxin occur on their own, and if detected at
an early stage, there may  be the possibility of reducing the progress
of Child A to Child C with antiviral treatment. When the liver stage
is in the Child-C category, it is an indication for liver transplantation
or mortality [12]. The data show that most of the end-stage liver
disease and CTP scores are linked with the presence of aﬂatoxin and
HBV, which indicates that these two together increase the severity
of the liver disease. Finally, on the one hand it is very important to
have good biomarker system for the detection of aﬂatoxin exposure
and its deleterious effects on human health. On the other hand, it
is always important to raise the awareness levels among different
stakeholders and to have proper regulatory limits to restrict the
free allowance of aﬂatoxin-contaminated products into the food
chain. The proper management of controlling aﬂatoxin exposure at
an early stage would help reduce the chance of getting a TP53 muta-
tion, and the patient would respond to the treatment to reduce the
viral load to reduce the severity of the liver disease.
5. Conclusions
This study compared 238 individuals with (130 HBV-positive)
or without liver disease (108 HBV-negative) by measuring the fre-
quency of TP53 mutation at codon 249 and the level of aﬂatoxin B1
adducts in albumin. Among the 130 HBV-positive patients, eight
were positive for the TP53 mutation and 29 for aﬂatoxin-albumin
adducts. Serum aﬂatoxin-albumin adducts, and mutation at posi-
tion 249 in the TP53 gene were detected in the DNA of blood samples
from patients with HBV infection and liver disorder. The severity
of the liver disease with HBV weakly correlated with the presence
and the level of aﬂatoxin-albumin adducts and with TP53 mutation
at codon 249 (p = 0.07).
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